Core Viewpoint - On September 28, Linuo Group celebrated its 31st anniversary, coinciding with the completion and commissioning of its subsidiary Koyuan Pharmaceutical's intelligent factory for injectable products [1] Group 1: Project Overview - The intelligent factory, characterized by "AI + computing power," was fully invested and constructed by Linuo Pharmaceutical, covering a total area of approximately 46,000 square meters [1] - The facility includes quality inspection and R&D buildings, high-end injectable production workshops, and a comprehensive intelligent storage warehouse [1] - The production and quality management systems are established according to national GMP, US FDA, and EU GMP standards, making it a high-end intelligent manufacturing plant for injectables [1] Group 2: Strategic Importance - The project is recognized as a key project for green, low-carbon, and high-quality development in Shandong Province, as well as a significant initiative for enterprise technological transformation and major industrial breakthroughs in the province [1] Group 3: Company Positioning - Koyuan Pharmaceutical is a leading player in the domestic chemical raw material drug sector, with its subsidiary Linuo Pharmaceutical focusing on formulations [1] - The company has built strong capabilities and competitive advantages in areas such as hypoglycemic agents, cardiovascular drugs, and central nervous system medications [1] - The completion of this project marks a significant transition for Koyuan Pharmaceutical and Linuo Pharmaceutical from oral solid formulations to the high-barrier injectable sector, accelerating the formation of a new industrial ecosystem with multiple dosage forms coexisting and thriving together [1]
新建成注射剂智能工厂 科源制药加快形成多剂型共存产业生态